Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
Avenue Therapeutics, Inc. announced that BAER-101 fully suppressed seizure activity in SynapCell's GAERS model of absence epilepsy, demonstrating high efficacy in anti-seizure drug development. The preclinical data showed full seizure suppression with a minimal effective dose of 0.3 mg/kg, PO, supporting its advancement to a Phase 2a trial.
Positive
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy.
The minimal effective dose of BAER-101 was 0.3 mg/kg, PO, with fast onset and stable effect.
The preclinical data supports the continued development of BAER-101 in a Phase 2a trial.
The presentation of the data will be at the ASENT 2024 Annual Meeting by Amy Chappell, M.D., FAAN.
The GAERS model is a reliable indicator of efficacy in anti-seizure drug development with high predictability of response in humans.
The recent findings on BAER-101's efficacy in the GAERS model of absence epilepsy are a pivotal development in the field of neurologic disease treatment. The GAERS model is a highly respected tool in preclinical testing for anti-seizure medications due to its strong correlation with human responses. The minimal effective dose and the fast onset of action observed with BAER-101 are critical factors that may indicate a favorable profile for human clinical trials. The drug's selective potentiation of α2- and α3-containing GABAA receptors is a targeted approach that could offer specificity in treatment and potentially fewer side effects compared to non-selective therapies.
From a medical research perspective, the transition from preclinical models to human trials is fraught with uncertainty. However, the robust preclinical data set, which includes both efficacy and safety/tolerability profiles, provides a solid foundation for the upcoming Phase 2a trials. The ability to suppress seizure activity completely is a significant benchmark that sets a high expectation for the drug's performance in clinical settings. The implications for patients with absence epilepsy, a condition that can be debilitating and difficult to manage, could be profound if the drug's efficacy translates to human trials.
Avenue Therapeutics' announcement regarding BAER-101 has potential implications for the company's financial outlook. The successful preclinical results may positively influence investor sentiment, as they suggest a progression to more advanced stages of drug development. The specialty pharmaceutical market, particularly in neurologic diseases, is a high-value sector with significant unmet needs. A novel and effective anti-seizure medication could capture a substantial market share, especially given the specificity of BAER-101's mechanism of action.
Investors will be closely monitoring the progression to Phase 2a trials, as clinical success rates will heavily influence the drug's commercial prospects and, by extension, Avenue's revenue potential. The company's stock performance on Nasdaq may see heightened volatility around key milestones in the drug's development. It is essential to consider the competitive landscape and the regulatory pathway ahead, as these factors will also shape the financial implications of BAER-101's development journey.
The selective potentiation of α2- and α3-containing GABAA receptors by BAER-101 represents a nuanced approach to modulating neuronal activity to prevent seizures. GABAA receptors are pivotal in mediating inhibitory neurotransmission in the brain and their role in epilepsy has been extensively studied. By focusing on specific subunits, BAER-101 may offer an improved safety profile and efficacy over broad-spectrum GABAergic drugs. This specificity is particularly relevant given the complex nature of epilepsy and the need for treatments that minimize adverse effects while providing effective control of seizure activity.
Moreover, the pharmacokinetics of BAER-101, suggested by the minimal effective dose and stability of the effect, will be key areas of investigation in the Phase 2a trials. Understanding how the drug is metabolized and distributed in the body will inform dosing regimens and patient compliance considerations. The pharmacological community will be looking for data on the drug's interaction with other medications, as polypharmacy is common in epilepsy management.
03/11/2024 - 08:00 AM
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of response in humans
MIAMI, March 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of epilepsy at the American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting on Wednesday, March 13, 2024.
The Company's presentation details are as follows:
Title : BAER-101, a Selective Potentiator of α2- and α3-containing GABAA Receptors, Fully Suppresses Spontaneous Cortical Spike-Wave Discharges in Genetic Absence EpilepsyFormat: Platform PresentationSession Date/Time : Wednesday, March 13, 2024, from 1:30-3:00pm ET Location : Regency I
BAER-101 underwent preclinical in vivo evaluation in SynapCell's GAERS model of absence epilepsy. The GAERS model, which is a proven, early, informative indicator of efficacy in anti-seizure drug development with high predictability of response in humans, mimics behavioral, electrophysiological and pharmacological features of human absence seizures. In the model, BAER-101 demonstrated full suppression of seizure activity with a minimal effective dose of 0.3 mg/kg, PO. The effect was fast in onset and stable throughout the duration of testing. The combination of safety and tolerability in hundreds of patients and the preclinical efficacy data support BAER-101’s continued development in a Phase 2a trial.
The Company’s poster at ASENT 2024 will be available on the Publications section of Avenue’s website at https://avenuetx.com/publications/ .
About BAER-101 A receptors with minimal activity at α1 or α5‐containing receptors, which are believed to mediate many of the issues impacting the medical use of benzodiazepines such as those noted with diazepam use (tolerance, dependence, abuse, sedation and impaired cognition). As a result, BAER-101 may have the potential to treat epilepsy, anxiety and other disorders in which benzodiazepines are currently used, while minimizing the benzodiazepine associated adverse effects. BAER-101 was licensed in from AstraZeneca with a large safety database in over 700 patients and an efficacy signal in a subset of patients with anxiety.
About Epilepsy
About Avenue Therapeutics Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABAA α2, α3 receptor positive allosteric modulator for CNS diseases, and IV tramadol, which is in Phase 3 clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com .
Forward-Looking Statements This press release contains predictive or “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of current or historical fact contained in this press release, including statements that express our intentions, plans, objectives, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “should,” “would” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations, estimates and projections made by management about our business, our industry and other conditions affecting our financial condition, results of operations or business prospects. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due to numerous risks and uncertainties. Factors that could cause such outcomes and results to differ include, but are not limited to, risks and uncertainties arising from: expectations for increases or decreases in expenses; expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidate or any other products we may acquire or in-license; our use of clinical research centers and other contractors; expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities; expectations for generating revenue or becoming profitable on a sustained basis; expectations or ability to enter into marketing and other partnership agreements; expectations or ability to enter into product acquisition and in-licensing transactions; expectations or ability to build our own commercial infrastructure to manufacture, market and sell our product candidates; acceptance of our products by doctors, patients or payors; our ability to compete against other companies and research institutions; our ability to secure adequate protection for our intellectual property; our ability to attract and retain key personnel; availability of reimbursement for our products; estimates of the sufficiency of our existing cash and cash equivalents and investments to finance our operating requirements, including expectations regarding the value and liquidity of our investments; the volatility of our stock price; expected losses; expectations for future capital requirements; and those risks discussed in our filings which we make with the SEC. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.
Contact: ir@avenuetx.com
What did BAER-101 demonstrate in SynapCell's GAERS model of absence epilepsy?
BAER-101 fully suppressed seizure activity in the GAERS model.
What was the minimal effective dose of BAER-101 in the model?
The minimal effective dose of BAER-101 was 0.3 mg/kg, PO.
Where will the preclinical data be presented?
The preclinical data will be presented at the ASENT 2024 Annual Meeting.
Who will be presenting the data at the meeting?
Amy Chappell, M.D., FAAN will be presenting the data.
What is the GAERS model known for in anti-seizure drug development?
The GAERS model is a reliable indicator of efficacy with high predictability of response in humans.
